Q32 Bio Valuation
Is DB0 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of DB0 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate DB0's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate DB0's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for DB0?
Key metric: As DB0 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is DB0's PB Ratio? | |
|---|---|
| PB Ratio | 16.3x |
| Book | US$18.30m |
| Market Cap | US$299.04m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | -15.8x |
| Enterprise Value/EBITDA | -3x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does DB0's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 12.6x | ||
VSC 4SC | 44x | n/a | €48.2m |
HPHA Heidelberg Pharma | 2.9x | -33.0% | €103.9m |
FYB Formycon | 1.4x | 31.5% | €827.2m |
BIO3 Biotest | 2x | 29.3% | €1.4b |
DB0 Q32 Bio | 16.3x | -31.7% | €299.0m |
Price-To-Book vs Peers: DB0 is expensive based on its Price-To-Book Ratio (16.3x) compared to the peer average (12.6x).
Price to Book Ratio vs Industry
How does DB0's PB Ratio compare vs other companies in the DE Biotechs Industry?
Price-To-Book vs Industry: DB0 is expensive based on its Price-To-Book Ratio (16.3x) compared to the European Biotechs industry average (2.4x).
Price to Book Ratio vs Fair Ratio
What is DB0's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 16.3x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate DB0's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €25.60 | €79.96 +212.4% | 12.1% | €92.62 | €62.98 | n/a | 6 |
| Nov ’25 | €43.20 | €74.01 +71.3% | 21.7% | €92.71 | €50.06 | n/a | 6 |
| Oct ’25 | €39.60 | €70.29 +77.5% | 23.5% | €90.35 | €48.79 | n/a | 5 |
| Sep ’25 | €35.00 | €60.38 +72.5% | 30.2% | €91.49 | €45.75 | n/a | 4 |
| Aug ’25 | €34.80 | €57.44 +65.1% | 35.4% | €92.27 | €41.52 | n/a | 4 |
| Jul ’25 | n/a | €58.00 0% | 35.4% | €93.18 | €41.93 | n/a | 4 |
| Jun ’25 | n/a | €45.75 0% | 7.4% | €49.74 | €41.45 | n/a | 3 |
| May ’25 | n/a | €44.21 0% | 5.3% | €46.54 | €41.89 | n/a | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
Aspen Pharmacare Holdings
R75.5b
Manufactures and supplies specialty and branded pharmaceutical products worldwide.
LDZA
R8.95
7D
0.6%
1Y
4.7%
Amneal Pharmaceuticals
US$2.6b
Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.
2DT
US$7.70
7D
-4.3%
1Y
91.5%
Almirall
€1.8b
A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.
E2Z
€8.29
7D
-1.8%
1Y
0.2%